Brief: Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis

YARROW BIOSCIENCE

19/02/2025 15:02

Feb 19 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS INITIATES PHASE 1B TRIAL OF VYN202, A
NOVEL
BD2-SELECTIVE ORAL BET INHIBITOR, IN PLAQUE PSORIASIS

Source text:  ID:nGNX96vXMt 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))